Cravings Study presented by Dr. Susan Broom and Dr. Richard Mestayer III
Society of Neuroscience Convention, 2014
Intravenous Administration of Nicotinamide Adenine Dinucleotide Significantly Reduces Self Report Craving Ratings Associated with Opiate and Alcohol Withdrawal
S. L. BROOM1, R. MESTAYER2, E. STULLER3, D. COOK4, J. CARSON2, K. SIMONE2, P. NORRIS2, P. HOTARD21 Dept Psychol, William Carey Univ., Hattiesburg, MS; 2Springfield Wellness Center, Springfield, LA; 3Stullerresettings, LLC; 4ABAM.SoberMD, LLC.
Treatment of substance abuse
disorders continues to challenge clinicians and “cravings” for the abused
substance are often impediments to sobriety. Nicotinamide Adenine Dinucleotide
(NAD) has been used in the past with claims of having anti-craving properties.
Previous data from this clinic using a similar formulation of NAD support the
use of NAD as a valid treatment for drug cravings. This pilot study
retrospectively examined the anti-craving properties of NAD in a group of 60
patients. Additionally, patients were assessed on severity of cravings and
relapse episodes at 12-20 months post treatment.
The patients were adult males and females with addictions to primarily opiates or alcohol (N=60). Six patients were omitted due to incomplete data. The treatment, Brain Restoration Plus (BR+) TM comprised of intravenous infusions of NAD as well as vitamins, oral amino acids, NAC and variable PRN medications for an average of 10 consecutive days ranging from 5 to 10 hours daily at a dose range of 500mg-1500mg each day.
Self-reported craving ratings (0-10 Scale) were collected on Day 1 (before starting treatment), Day 5, and on Day 10 (last day of treatment). Follow up phone surveys were conducted from 12-20 months post treatment (N= 27). Patients reported severity of cravings (1-5) and number of relapse episodes at the present time.